Iacopo Petrini

Associate Professor

University of Pisa

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Iacopo Petrini is an Associate Professor at the University of Pisa, Italy. His research focuses on oncological and hematological malignancies, with recent articles exploring the prognostic stratification of mesothelioma, the role of hypoxia in stemness of progenitor cells, and the molecular mechanisms of cardiovascular toxicity in cancer treatments. He is also involved in studies related to thymic carcinomas and advanced sequencing techniques for cancer diagnostics.

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Sebastian Schölch

Head

German Cancer Research Center (DKFZ)

GERMANY

View details

Marco Lucchi

University of Pisa

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Iacopo Petrini

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network

Single-cell sequencing has revealed a more complex array of thymic epithelial cells

Hypoxia Promotes the Stemness of Mesangiogenic Progenitor Cells and Prevents Osteogenic but not Angiogenic Differentiation

Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management

Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas

Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies.

Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing

Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.

Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation.

ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach.

Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.

Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients.

Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone.

Collaborators (2)

Sebastian Schölch

Marco Lucchi

Make your next move.